Honing the Indications for Adjuvant CDK4/6 Inhibition in Breast Cancer
Defining high risk, considering role of Ki-67, BRCA mutations
Source: medpagetoday.com
Page 5 - Virtual Plenary News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Virtual Plenary. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Virtual Plenary Today - Breaking & Trending Today
Karyopharm Provides U.S. Regulatory Update on Selinexor in Advanced or Recurrent Endometrial Cancer
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today provided an...
Source: prnewswire.com
An 'Intriguing Failure' in Advanced, Pre-Treated GIST
Second-line ripretinib unable to best sunitinib, but still had meaningful clinical activity
Source: medpagetoday.com
Innovent Announces NMPA of China Acceptance of a Supplemental New Drug Application for TYVYT® (Sintilimab Injection plus Bevacizumab Biosimilar Injection and Chemotherapy in Patients with EGFR-mutated Non-squamous Non-small Cell Lung…
SAN FRANCISCO and SUZHOU, China, Dec. 24, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced that the National Medical Products Administration (NMPA) of China has accepted the supplemental New Drug Application (sNDA) for...
Source: asiaone.com
Innovent Releases the ORIENT-31 Phase 3 Study First Interim Analysis Results of Sintilimab plus BYVASDA (bevacizumab biosimilar injection) and Chemotherapy in Patients with EGFR-mutated Nonsquamous Non-small Cell Lung Cancer who Progressed…
SAN FRANCISCO and SUZHOU, China, Nov. 22, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, today announced first interim analysis results of the randomized, double-blinded, multi-center Phase 3 ORIENT-31 study conducted in China evaluating sintilimab...
Source: asiaone.com